CLINICAL
RESEARCH
Sher Allergy Specialists operates a clinical research program under the supervision of Dr. Mandel Sher who has been conducting clinical studies for over 20 years.
Our clinical research program has contributed to the medications and devices that are now state-of-the-art allergic and respiratory care. All of our clinical studies are approved and overviewed by the Food and Drug Administration (FDA). Clinical Research, also known as “clinical studies” or “clinical trials,” is another way Sher Allergy’s experienced research team offers our children and adult patients, and almost anyone who is not yet a patient but is interested in participating in a clinical trial, the opportunity to help others and possibly help themselves. Clinical trials evaluate the safety and efficacy of novel medications and medical devices. The clinical research may directly benefit you by offering a treatment option that is not yet available to the public and may produce a better outcome or experience than your current situation. We invite you to call today to see if there is a study for you.
In appreciation for your voluntary participation, most clinical studies offer payment for time and travel. You do not need to have health insurance to participate. In addition to having access to the study medication or device, clinical research volunteers may benefit from related doctor visits, labs, physical exam, and other medical tests at no cost. Every clinical research study has a specific purpose and eligibility criteria. Our friendly and expert clinical research team will look forward to hearing about your interest and seeing if there is a current or upcoming study for which you are a fit. For more information or to see if you qualify for a current study, please call to speak with one of our experienced and friendly team.
​
Current and Recent Clinical
Research Studies
Current and recent clinical research trials have studied: Allergic Rhinitis, Asthma, Chronic Cough, Chronic Sinusitis, Idiopathic Pulmonary Fibrosis, Immunodeficiency Disease, Juvenile Rheumatoid Arthritis, Nasal Polyps, and Peanut Allergy.
​
Bellus Cough Study BUS-P2-02
-
“A randomized, adaptive, double-blind, placebo-controlled, parallel-arm, phase 2b study to evaluate the efficacy and safety of multiple doses of BLU-5937 in adult participants with refractory chronic cough.”
Bayer Cough Study 20392
-
“A randomized, double-blind, parallel group, phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractor and/or unexplained chronic cough.”
Shionogi S-600918
-
“A Phase 2-b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in patients with Refractory Chronic Cough.”
Optinose OPN-FLU-CS-3206
“A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372μg of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps.”
Bellus/Illingworth BUS-PN-01
-
Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough “(RELIEF).”
Merck
-
“A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027)."
ARC008 ‘Ramses’
-
“Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years.”
ARC007 ‘Ramses’
-
“Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years.”
AF219-012
“A Phase 2b 12 Week Study to Assess the Efficacy and Safety of AF-219, in Subjects with Treatment Refractory Chronic Cough.”
AF219-021
“A Phase 2b Randomized Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219, in Subjects with Treatment Refractory Chronic Cough.”
AF219-010
“A Phase II Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects with Refractory Chronic Cough.”
OPN-FLU-CS-3204
-
“A 3-month open-label multicenter study evaluating the safety of intranasal administration of 400ug of Fluticasone Propionate twice a day (BID) using a novel bi-directional device in subjects with chronic sinusitis with or without nasal polyps.”
ARC011 ‘Ramses’
-
“Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years.”